Pancreatic Cancer in Older Adults: Navigating Treatment Options
"A comprehensive guide to understanding and managing pancreatic adenocarcinoma in the aging population, offering insights into current treatment strategies and considerations for improved care."
Pancreatic cancer, while not the most common cancer, ranks as the third leading cause of cancer-related deaths in the United States. In 2018 alone, projections estimated 55,440 new cases and 44,330 deaths. This disease presents a significant challenge, particularly because early detection is rare due to nonspecific symptoms that often manifest only in advanced stages. As a result, the five-year overall survival rate remains dismally low at approximately 8%.
One of the critical aspects of pancreatic cancer is its prevalence among older adults. The median age at diagnosis is 71 years, with only a fraction of cases diagnosed before age 50. Current guidelines from the National Comprehensive Cancer Network (NCCN) advocate surgery for localized disease, followed by adjuvant therapy and potential enrollment in clinical trials. For metastatic disease, the guidelines suggest clinical trial participation or systemic chemotherapy, drawing from landmark trials like ACCORD-11 and MPACT.
However, a significant caveat exists: these pivotal trials primarily involved younger, fitter patients. ACCORD-11 excluded individuals over 75, and MPACT included 92% of participants with a Karnofsky performance score above 80, indicating a high level of functional ability. This discrepancy raises concerns about the applicability of these findings to the older adult population, who often have comorbidities and varying levels of fitness. This article addresses this gap by examining available evidence regarding optimal treatment strategies for older adults diagnosed with pancreatic cancer.
Age and U.S. Incidence
SEER reports that pancreatic cancer becomes more common with age and is slightly more common in men than women. For 2019–2023, the age-adjusted rate of new cases was 13.9 per 100,000 people per year. All Seniors likewise describes pancreatic cancer as more prevalent among older adults.
Treatment Depends on Disease Setting
A 2024 review reports that surgery is typically recommended for localized pancreatic tumors, while chemotherapy is preferred for advanced or metastatic disease. It gives the average age at diagnosis as 72. A separate review notes that pancreatic cancer disproportionately affects older adults and that its prevalence is expected to rise over the coming decade as the population ages. It also identifies a need for further research into geriatric factors and how they influence outcomes.
Surgical Interventions: Balancing Benefits and Risks in the Elderly
For localized pancreatic cancer, surgical resection remains the primary curative option. Yet, a recurring theme in the literature is that older patients are significantly less likely to undergo surgery compared to their younger counterparts, regardless of their overall health status. A study using the Surveillance, Epidemiology, and End Results (SEER) database revealed that increasing age independently correlated with reduced surgical intervention rates.
- Compared to patients aged 65–69, the odds of receiving surgery decreased for those aged 70–74 (OR 0.84), 75–79 (OR 0.74), 80–84 (OR 0.52), and ≥85 (OR 0.39).
- Other factors influencing the likelihood of surgery included gender and race, though these were not statistically significant. Larger tumor size (≥2 cm) significantly reduced the odds of surgical intervention (OR 0.33).
- Another study reinforced these findings, showing a significant decline in resection rates with advancing age, from 39% in those under 70 to just 5% in patients aged 85 and older.
Guideline-Based First-Line Treatment
A real-world study of metastatic pancreatic ductal adenocarcinoma describes the American Society of Clinical Oncology's updated 2020 treatment guidelines. It reports that first-line treatment recommendations depend on Eastern Cooperative Oncology Group performance status and comorbidity profile. For patients with ECOG performance status 0–1 and a favorable comorbidity profile, FOLFIRINOX is recommended; gemcitabine plus nab-paclitaxel is an option for patients with a relatively favorable comorbidity profile.
Evidence Gaps in Older Patients
A propensity score-matched comparison of gemcitabine plus nab-paclitaxel (GnP) with gemcitabine alone in older adults with unresectable pancreatic cancer notes that potential bias remained, including background differences between treatment groups and missing clinical-outcome data such as geriatric assessments. A subgroup analysis of the pivotal NAPOLI 3 trial says the risk–benefit profile of intensive chemotherapy in older patients with metastatic pancreatic cancer needs further investigation. It points to limited use of intensive management in practice and underrepresentation of older adults in clinical trials. Patients aged 76 or older were ineligible for the pivotal PRODIGE 4/ACCORD 11 FOLFIRINOX trial.
Looking Ahead: Optimizing Care for Older Adults with Pancreatic Cancer
The existing research indicates that healthy, fit older adults should receive standard treatments, while recognizing that survival benefits from surgery, radiation, and chemotherapy may diminish with age. Careful risk-benefit assessments for each treatment are essential, especially for surgical interventions where postoperative mortality increases with age. Older patients were often excluded from major trials like ACCORD11 (excluding those over 75 with metastatic disease) and LAP-07 (excluding those over 70 with locally advanced disease), limiting the applicability of findings to this demographic.
Aging and Disease Burden
A study of global, regional, and national burdens evaluates pancreatic cancer and pancreatitis among adults aged 70 and older from 1990 to 2021. The Precede Foundation describes pancreatic cancer as more prevalent in the aging population, with higher incidence and mortality rates observed among older adults. Together, these sources highlight the importance of understanding the disease burden in older populations, though the provided study snippet does not give specific burden estimates.
Treatment Outcomes and Personal Experience
Research on metastatic pancreatic ductal adenocarcinoma reports that older patients can experience meaningful responses to treatment; the study evaluated patient characteristics, treatment rates, and survival outcomes by age at diagnosis. A Pancreatic Cancer Action case study recounts Sue Nicholls' reflection on her daughter Sarah, who died of pancreatic cancer in February 2024 at age 49. Sue describes Sarah's symptoms being missed by doctors and finding strength through fundraising. Sarah's story illustrates an individual experience, but it is not evidence about outcomes specifically in older adults.